- Moderna (MRNA) says a booster dose of its vaccine appears to protect against omicron.
- Moderna (MRNA) shares boosted themselves, up 7% premarket.
- Moderna (MRNA) stock has reversed the post-earnings slide.
Moderna (MRNA) is back to pre-earnings levels as the emergence of the omicron variant and its effect flows through to multiple vaccine makers. Booster rollouts are ongoing globally and the spread of the new variant is causing new restrictions to be put in place in many European countries. Moderna shares have now retraced back to where they were on November 4, just before a disappointing earnings release. Now, this next phase will be crucial. Can traders push Moderna (MRNA) higher or will longer-term investors hold sway and take a second opportunity for more selling.
Moderna (MRNA) stock news
The White House has chimed in on the latest covid news as it struggles to cope with the omicron variant. It released an unusually strong statement on Friday urging continued vaccination.
"Our vaccines work against Omicron, especially for people who get booster shots when they are eligible. If you are vaccinated, you could test positive. But if you do get COVID, your case will likely be asymptomatic or mild. We are intent on not letting Omicron disrupt work and school for the vaccinated. You’ve done the right thing, and we will get through this. For the unvaccinated, you’re looking at a winter of severe illness and death for yourselves, your families, and the hospitals you may soon overwhelm. So, our message to every American is clear: There is action you can take to protect yourself and your family. Wear a mask in public indoor settings. Get vaccinated, get your kids vaccinated, and get a booster shot when you’re eligible". Here is the link for you to verify the statement.
Moderna (MRNA) this morning announced that its authorized booster shot increases omicron neutralizing antibodies approximately 37 fold. The Centre for Disease Control (CDC) had on Friday backed mRNA vaccines over JNJ. Also on Friday Bloomberg reported that researchers from the University of Washington and Humbas Biomed produced results from a study showing limited antibody response against omicron from Sinopharm, Sputnik and JNJ covid vaccines. The study is pre-print and not peer-reviewed.
Moderna (MRNA) stock forecast
The emergence of omicron had already stabilized losses in Moderna (MRNA) stock and resulted in a higher high on November 29 and a lower low on December 10. The news of this booster effectiveness will see more gains for MRNA shares. November 29 resistance at $376 will be the first target. But in reality, this zone from $320 to $350 (highlighted below) is a resistance zone with decent volume. The spike high in late November was just when news of omicron began to surface and investors rushed back to covid vaccine stocks. Equity markets then began to discount its effect and MRNA slid back. But crucially it set a higher low. We expect further gains here. The RSI has plenty of room to run and yet to signal a significant move. The MACD had already crossed bullishly so more is expected. Breaking above $376 will see a test of $420 to $450. Key supports are the 200-day moving average t $268 and the Dec 10 low at $233.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trades firmer near 1.0350 as traders brace for German Retail Sales, FOMC Minutes
The EUR/USD pair gains ground to near 1.0350 during the early European session on Wednesday. However, the potential upside of the major pair might be limited amid the prospects for slower interest rate cuts by the Federal Reserve in 2025.
GBP/USD hovers below nine-day EMA near 1.2500
The GBP/USD pair maintains its position after registering losses in the previous session, hovering around 1.2480 during Wednesday's Asian hours. Technical analysis on the daily chart points to a weakening bearish trend, as the pair is trading above the upper boundary of a descending channel pattern.
Gold eyes US ADP report and Fed Minutes for next push higher
Gold price is consolidating the previous rebound near $2,650 early Wednesday, awaiting the US ADP jobs report and the Minutes of the US Federal Reserve December meeting for the next leg higher.
DOGE and SHIB traders book profits at the top
Dogecoin and Shiba Inu prices broke below their key support levels on Wednesday after declining more than 9% the previous day. On-chain data provider Santiments Network Realized Profit/Loss indicator shows massive spikes in these dog-theme memecoins, indicating traders realize profits.
Five fundamentals for the week: Nonfarm Payrolls to keep traders on edge in first full week of 2025 Premium
Did the US economy enjoy a strong finish to 2024? That is the question in the first full week of trading in 2025. The all-important NFP stand out, but a look at the Federal Reserve and the Chinese economy is also of interest.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.